<article><p>Alvogen’s private equity owners including CVC Capital Partners are exploring options for the generic pharmaceutical company, which could be valued at about $4 billion, according to people familiar with the matter.</p></article>

<p>Alvogen’s private equity owners including CVC Capital Partners are exploring options for the generic pharmaceutical company, which could be valued at about $4 billion, according to people familiar with the matter.</p>
<p>The controlling shareholders of the drugmaker have held on-and-off talks with Shanghai Pharmaceuticals Holding Co. focusing on a sale of Alvogen’s U.S. business, the people said. Alvogen would keep its operations in Asia as well as central and eastern Europe, one of the people said, asking not to be identified because the information is private.</p>
<p>While they are not running a formal auction process, Alvogen’s owners may look to hold discussions with other international buyers, the people said. Deliberations are at an early stage, and there’s no certainty they will lead to a transaction, according to the people.</p>
<p>A consortium including CVC and Singapore state investment company Temasek Holdings Pte bought a controlling stake in Alvogen in 2015 for about $2 billion, people with knowledge of the matter said at the time.</p>
<p>Shanghai Pharma has stepped up its hunt for investments after missing out on the purchase of German generic drugmaker Stada Arzneimittel AG. The company is currently bidding for a stake in Arbor Pharmaceuticals LLC as well as  Cardinal Health Inc.’s Chinese distribution business, people familiar with the matter have said.</p>
<h3>Manufacturing Facilities</h3>
<p>Any deal would add to the $236 billion of health-care acquisitions announced this year, according to data compiled by Bloomberg. The biggest market for Alvogen is the U.S., where it sells generic pharmaceuticals and provides third-party services such as contract manufacturing and clinical research. It operates a manufacturing facility in Norwich, New York under the Norwich Pharmaceuticals brand.</p>
<p>Representatives for CVC and Shanghai Pharma declined to comment. A spokesman for Alvogen didn’t answer a phone call and an email seeking comment outside of regular business hours. Temasek said in an emailed statement it doesn’t comment on rumors or speculation.</p>
<p>Alvogen has 350 marketed products spanning a range of therapeutic areas including oncology, cardiology, respiratory and neurology, according to its website. It develops, manufactures and sells generic drugs, branded medicines, biosimilar products and over-the-counter products like cosmetics and food supplements.</p>
<p>The company also has a plant in Romania and a packaging center in Serbia. It has made three acquisitions since 2012 in Taiwan, where it operates under the Lotus Pharmaceuticals brand, and South Korea combined. Part of its Asian operations are listed as Seoul-traded Alvogen Korea Co., which has a market value of about $285 million.</p>
<h4><em>Bloomberg</em></h4>


Alvogen’s private equity owners including  CVC Capital are exploring options for the generic pharma company, which could be valued at about $4 billion

PE owners said to mull sale options for Temasek-backed drug-maker Alvogen

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

PE owners said to mull sale options for Temasek-backed drug-maker Alvogen

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief